Smartlab Europe

Press Releases

Merck Launches First Commercially Available Equine-Specific Multiplex Assay for Protein Biomarkers

Merck, a leading science and technology company, today announced the global launch of the first commercially-available equine-specific multiplex assay for protein biomarkers. The assay is intended for research use only, not for use in diagnostic procedures. ...

Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

Phase III study met all co-primary and secondary endpoints and achieved statistically significant resultsWorld pharma today/-press releases/-Allergan Plc and Gedeon Richter Plc. announced positive results from Venus I, one of two pivotal Phase III clinical trials evaluating the efficacy...

Successful ExCeL debut for Infrarail and CITE 2016

With unprecedented levels of rail investment and the rise of national infrastructure up the political agenda, there was an upbeat mood at the Infrarail 2016 exhibition of railway infrastructure products and services and at CITE 2016, covering the civil...

Reed Sinopharm Hosts World’s Largest Healthcare Event – tHIS in Shanghai

SHANGHAI, April 21, 2016 /PRNewswire/ -- The Health Industry Summit (tHIS) 2016 opened in Shanghai at the National Exhibition and Convention Center on April 17. The organizer posted a record 380,000 entry scans, 216,784 professional visitors and...

AstraZeneca completes divestment of Imdur to China Medical System Holdings

AstraZeneca announced that it has completed the divestment of the global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive $190...

European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® (ibrutinib)

AbbVie, a global biopharmaceutical company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion in favor of the use of IMBRUVICA® (ibrutinib) for the treatment of adult...

Biogen Appoints Michael Ehlers Executive Vice President, Research and Development

Biogen announced the appointment of Michael Ehlers, M.D., Ph.D., as executive vice president, Research and Development. World pharma today/Press releases /-Dr. Ehlers will oversee Biogen’s global Research, Drug Discovery, Clinical Development, and Medical Affairs functions, defining...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »